Madrigal Pharmaceutical

The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease.

The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: The fatty liver disease known as nonalcoholic steatohepatitis, or NASH.

The US Food and Drug Administration (FDA) on Thursday approved the first medication for people with a severe type of non-alcoholic fatty liver disease.

The race is on to identify the wonder drug that will treat an increasingly common consequence of obesity: The fatty liver disease known as nonalcoholic steatohepatitis, or NASH.